Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Stemline Therapeutics

DB:S46
Snowflake Description

Excellent balance sheet with high growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
S46
DB
$224M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Stemline Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of oncology therapeutics in the United States and internationally. The last earnings update was 23 days ago. More info.


Add to Portfolio Compare Print
  • Stemline Therapeutics has significant price volatility in the past 3 months.
S46 Share Price and Events
7 Day Returns
1.9%
DB:S46
5.2%
DE Biotechs
4.3%
DE Market
1 Year Returns
-65.3%
DB:S46
-7.4%
DE Biotechs
-14.2%
DE Market
S46 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Stemline Therapeutics (S46) 1.9% -0.9% -54% -65.3% -43.9% -70.9%
DE Biotechs 5.2% -3.3% -20.3% -7.4% 19.5% -9.4%
DE Market 4.3% -9% -21.6% -14.2% -19.6% -25.6%
1 Year Return vs Industry and Market
  • S46 underperformed the Biotechs industry which returned -7.4% over the past year.
  • S46 underperformed the Market in Germany which returned -14.2% over the past year.
Price Volatility
S46
Industry
5yr Volatility vs Market
Related Companies

S46 Value

 Is Stemline Therapeutics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Stemline Therapeutics to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Stemline Therapeutics.

DB:S46 Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 9 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 5.2%
Perpetual Growth Rate 10-Year DE Government Bond Rate -0.4%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:S46
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate -0.4%
Equity Risk Premium S&P Global 5.4%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.05
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.048 (1 + (1- 21%) (0.62%))
1.036
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.04
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= -0.39% + (1.036 * 5.44%)
5.24%

Discounted Cash Flow Calculation for DB:S46 using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Stemline Therapeutics is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

DB:S46 DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 5.24%)
2020 -54.50 Analyst x2 -51.78
2021 -27.87 Analyst x4 -25.16
2022 -5.50 Analyst x2 -4.72
2023 24.00 Analyst x2 19.56
2024 57.00 Analyst x2 44.15
2025 86.78 Est @ 52.24% 63.86
2026 118.41 Est @ 36.45% 82.80
2027 148.49 Est @ 25.4% 98.66
2028 174.72 Est @ 17.66% 110.30
2029 196.12 Est @ 12.25% 117.64
Present value of next 10 years cash flows $455.00
DB:S46 DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= $196.12 × (1 + -0.39%) ÷ (5.24% – -0.39%)
$3,467.39
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $3,467.39 ÷ (1 + 5.24%)10
$2,079.81
DB:S46 Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $455.00 + $2,079.81
$2,534.81
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $2,534.81 / 47.37
$53.51
DB:S46 Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:S46 represents 0.90336x of NasdaqCM:STML
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.90336x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (USD) x Listing Adjustment Factor
= $ 53.51 x 0.90336
€48.34
Value per share (EUR) From above. €48.34
Current discount Discount to share price of €4.30
= -1 x (€4.30 - €48.34) / €48.34
91.1%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Stemline Therapeutics is available for.
Intrinsic value
>50%
Share price is €4.3 vs Future cash flow value of €48.34
Current Discount Checks
For Stemline Therapeutics to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Stemline Therapeutics's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Stemline Therapeutics's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Stemline Therapeutics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Stemline Therapeutics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:S46 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in USD $-1.83
NasdaqCM:STML Share Price ** NasdaqCM (2020-04-08) in USD $4.76
Europe Biotechs Industry PE Ratio Median Figure of 24 Publicly-Listed Biotechs Companies 43.07x
Germany Market PE Ratio Median Figure of 402 Publicly-Listed Companies 17.07x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Stemline Therapeutics.

DB:S46 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqCM:STML Share Price ÷ EPS (both in USD)

= 4.76 ÷ -1.83

-2.61x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Stemline Therapeutics is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Stemline Therapeutics is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Stemline Therapeutics's expected growth come at a high price?
Raw Data
DB:S46 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -2.61x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 9 Analysts
52%per year
Europe Biotechs Industry PEG Ratio Median Figure of 19 Publicly-Listed Biotechs Companies 1.71x
Germany Market PEG Ratio Median Figure of 256 Publicly-Listed Companies 1.24x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Stemline Therapeutics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Stemline Therapeutics's assets?
Raw Data
DB:S46 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in USD $3.46
NasdaqCM:STML Share Price * NasdaqCM (2020-04-08) in USD $4.76
Germany Biotechs Industry PB Ratio Median Figure of 14 Publicly-Listed Biotechs Companies 3.37x
Germany Market PB Ratio Median Figure of 573 Publicly-Listed Companies 1.47x
DB:S46 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqCM:STML Share Price ÷ Book Value per Share (both in USD)

= 4.76 ÷ 3.46

1.38x

* Primary Listing of Stemline Therapeutics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Stemline Therapeutics is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Stemline Therapeutics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Stemline Therapeutics has a total score of 3/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

S46 Future Performance

 How is Stemline Therapeutics expected to perform in the next 1 to 3 years based on estimates from 9 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
52%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Stemline Therapeutics expected to grow at an attractive rate?
  • Stemline Therapeutics's earnings growth is expected to exceed the low risk savings rate of -0.4%.
Growth vs Market Checks
  • Stemline Therapeutics's earnings growth is expected to exceed the Germany market average.
  • Stemline Therapeutics's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:S46 Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:S46 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 9 Analysts 52%
DB:S46 Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 9 Analysts 32.4%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 38.2%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.2%
Germany Market Earnings Growth Rate Market Cap Weighted Average 14.1%
Germany Market Revenue Growth Rate Market Cap Weighted Average 3.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:S46 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 9 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:S46 Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 250 34 5
2023-12-31 193 1 5
2022-12-31 135 9 -26 7
2021-12-31 99 -28 -43 8
2020-12-31 61 -47 -65 9
2020-04-08
DB:S46 Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-12-31 43 -68 -77
2019-09-30 31 -75 -86
2019-06-30 18 -80 -92
2019-03-31 6 -77 -94
2018-12-31 1 -72 -85
2018-09-30 1 -67 -80
2018-06-30 1 -62 -75
2018-03-31 1 -57 -72
2017-12-31 1 -50 -68
2017-09-30 1 -43 -56
2017-06-30 1 -36 -50
2017-03-31 1 -30 -44

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Stemline Therapeutics's earnings are expected to grow significantly at over 20% yearly.
  • Stemline Therapeutics's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:S46 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 9 Analyst Estimates (S&P Global) See Below

All data from Stemline Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:S46 Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31 0.55 1.90 -0.21 5.00
2023-12-31 0.02 1.15 -0.60 5.00
2022-12-31 -0.48 0.26 -1.08 7.00
2021-12-31 -0.83 0.11 -1.37 8.00
2020-12-31 -1.31 -0.78 -1.54 9.00
2020-04-08
DB:S46 Past Financials Data
Date (Data in USD Millions) EPS *
2019-12-31 -1.83
2019-09-30 -2.28
2019-06-30 -2.71
2019-03-31 -3.03
2018-12-31 -2.99
2018-09-30 -2.96
2018-06-30 -2.93
2018-03-31 -2.95
2017-12-31 -2.94
2017-09-30 -2.59
2017-06-30 -2.47
2017-03-31 -2.33

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Stemline Therapeutics will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess Stemline Therapeutics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Stemline Therapeutics has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

S46 Past Performance

  How has Stemline Therapeutics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Stemline Therapeutics's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Stemline Therapeutics does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Stemline Therapeutics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Stemline Therapeutics's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Stemline Therapeutics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Stemline Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:S46 Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 43.22 -76.82 66.85
2019-09-30 31.39 -85.77 65.22
2019-06-30 18.06 -91.93 59.46
2019-03-31 5.55 -94.01 49.08
2018-12-31 0.50 -85.02 39.06
2018-09-30 0.50 -80.14 29.42
2018-06-30 0.80 -75.15 23.93
2018-03-31 0.60 -71.68 19.79
2017-12-31 0.90 -67.83 19.21
2017-09-30 1.20 -56.09 17.14
2017-06-30 1.20 -49.96 16.18
2017-03-31 1.14 -43.82 14.56
2016-12-31 1.04 -38.30 12.06
2016-09-30 0.95 -38.47 11.55
2016-06-30 0.85 -37.78 10.59
2016-03-31 0.74 -38.61 9.88
2015-12-31 0.65 -37.24 8.83
2015-09-30 0.57 -34.00 8.23
2015-06-30 0.44 -31.65 8.01
2015-03-31 0.39 -27.51 7.91
2014-12-31 0.34 -28.83 8.08
2014-09-30 0.28 -29.56 7.03 3.30
2014-06-30 0.21 -28.25 7.27 3.30
2014-03-31 0.14 -27.69 7.19 1.94
2013-12-31 0.07 -24.20 7.87
2013-09-30 -17.86 6.26 -2.42
2013-06-30 -14.22 4.96 -1.20

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Stemline Therapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Stemline Therapeutics has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Stemline Therapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Stemline Therapeutics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Stemline Therapeutics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

S46 Health

 How is Stemline Therapeutics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Stemline Therapeutics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Stemline Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Stemline Therapeutics's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Stemline Therapeutics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Stemline Therapeutics has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Stemline Therapeutics Company Filings, last reported 3 months ago.

DB:S46 Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 163.62 0.00 164.99
2019-09-30 175.43 0.00 175.02
2019-06-30 100.79 0.00 104.38
2019-03-31 108.89 0.00 124.54
2018-12-31 42.20 0.00 60.29
2018-09-30 63.54 0.00 78.60
2018-06-30 81.36 0.00 96.14
2018-03-31 88.02 0.00 99.51
2017-12-31 47.07 0.00 51.72
2017-09-30 66.24 0.00 65.53
2017-06-30 79.97 0.00 64.09
2017-03-31 93.22 0.00 89.65
2016-12-31 57.72 0.00 46.88
2016-09-30 65.81 0.00 50.50
2016-06-30 72.94 0.00 58.19
2016-03-31 80.59 0.00 49.22
2015-12-31 88.11 0.00 46.15
2015-09-30 97.33 0.00 53.08
2015-06-30 104.79 0.00 53.98
2015-03-31 113.47 0.00 92.90
2014-12-31 55.41 0.00 54.09
2014-09-30 61.20 0.00 44.60
2014-06-30 66.75 0.00 22.31
2014-03-31 71.75 0.00 24.41
2013-12-31 79.62 0.00 44.41
2013-09-30 86.21 0.00 87.67
2013-06-30 89.68 0.00 92.69
  • Stemline Therapeutics has no debt.
  • Stemline Therapeutics has not taken on any debt in the past 5 years.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Stemline Therapeutics has sufficient cash runway for 2.4 years based on current free cash flow.
  • Unable to confirm if Stemline Therapeutics has at least 1 year of cash runway based on growing free cash flows without relevant data.
X
Financial health checks
We assess Stemline Therapeutics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Stemline Therapeutics has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

S46 Dividends

 What is Stemline Therapeutics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Stemline Therapeutics dividends.
If you bought €2,000 of Stemline Therapeutics shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Stemline Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Stemline Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:S46 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 9 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 1.1%
Germany Market Average Dividend Yield Market Cap Weighted Average of 314 Stocks 3.6%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.6%
Germany Top 25% Dividend Yield 75th Percentile 4.6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:S46 Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2020-04-08

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Stemline Therapeutics has not reported any payouts.
  • Unable to verify if Stemline Therapeutics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Stemline Therapeutics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Stemline Therapeutics has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Stemline Therapeutics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Stemline Therapeutics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Stemline Therapeutics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

S46 Management

 What is the CEO of Stemline Therapeutics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Ivan Bergstein
COMPENSATION $9,441,653
AGE 53
TENURE AS CEO 16.7 years
CEO Bio

Dr. Ivan Bergstein, M.D., founded Stemline Therapeutics, Inc. in August 2003 and has been its Chairman, Chief Executive Officer and President. Dr. Bergstein served as the Medical Director of Keryx Biopharmaceuticals, Inc., (formerly Access Oncology, Inc.), where he was a key member of the team that in-licensed and developed several clinical stage oncology compounds. Prior to this, he served as Senior Biopharmaceuticals Analyst at Cancer Advisors (now Nitron Advisors). He serves as Director at Stemline Therapeutics, Inc since 2003. He received a BA in mathematics from the University of Pennsylvania and was elected to the Pi Mu Epsilon National Mathematics Honor Society, and then received an MD from the Mount Sinai School of Medicine where he was elected to the Alpha Omega Alpha Honor Medical Society, received the Merck Award for Clinical Excellence, and subsequently completed an internship in general surgery. He then became the Jerome A. Urban Post-Doctoral Research Fellow at the Cornell University Medical College where he studied and published work relating to Wnt genes in human breast cancer. He then completed an internal medicine residency and hematology-oncology fellowship at the New York Presbyterian Hospital—Weill Medical College of Cornell University where he studied and published work on gene therapy manipulations of the sonic hedgehog pathway.

CEO Compensation
  • Ivan's compensation has increased whilst company is loss making.
  • Ivan's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Stemline Therapeutics management team in years:

8.3
Average Tenure
54
Average Age
  • The average tenure for the Stemline Therapeutics management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Ivan Bergstein

TITLE
Founder
COMPENSATION
$9M
AGE
53
TENURE
16.7 yrs

David Gionco

TITLE
Senior VP of Finance & Chief Accounting Officer
COMPENSATION
$2M
AGE
59
TENURE
6.3 yrs

Ken Hoberman

TITLE
COO & Corporate Secretary
COMPENSATION
$8M
AGE
54
TENURE
8.3 yrs

Robert Francomano

TITLE
Chief Commercial Officer

John Salvagno

TITLE
Senior Vice President of Quality & Operations
Board of Directors Tenure

Average tenure and age of the Stemline Therapeutics board of directors in years:

6.5
Average Tenure
53
Average Age
  • The tenure for the Stemline Therapeutics board of directors is about average.
Board of Directors

Ivan Bergstein

TITLE
Founder
COMPENSATION
$9M
AGE
53
TENURE
16.7 yrs

Ron Bentsur

TITLE
Independent Director
COMPENSATION
$280K
AGE
53
TENURE
11.3 yrs

Ken Zuerblis

TITLE
Independent Director
COMPENSATION
$284K
AGE
60
TENURE
8.1 yrs

Alan Forman

TITLE
Independent Director
COMPENSATION
$291K
AGE
53
TENURE
5 yrs

Hagop Kantarjian

TITLE
Member of the Scientific Advisory Board

David Reardon

TITLE
Member of the Scientific Advisory Board

Patrick Wen

TITLE
Member of the Scientific Advisory Board

Owen O'Connor

TITLE
Member of the Scientific Advisory Board

Darren Cline

TITLE
Independent Director
COMPENSATION
$382K
AGE
55
TENURE
2 yrs

Daniel Hume

TITLE
Independent Director
COMPENSATION
$383K
AGE
52
TENURE
2 yrs
Who owns this company?
Recent Insider Trading
  • Stemline Therapeutics individual insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
03. Apr 20 Sell David Gionco Individual 01. Apr 20 01. Apr 20 -11,524 €4.38 €-50,480
20. Mar 20 Sell David Gionco Individual 16. Mar 20 16. Mar 20 -2,849 €3.48 €-9,906
13. Mar 20 Sell Kenneth Hoberman Individual 09. Mar 20 10. Mar 20 -26,191 €4.49 €-114,976
13. Mar 20 Sell Robert Francomano Individual 09. Mar 20 09. Mar 20 -1,266 €4.37 €-5,537
13. Mar 20 Sell Ivan Bergstein Individual 09. Mar 20 10. Mar 20 -57,451 €4.49 €-252,726
13. Mar 20 Sell David Gionco Individual 09. Mar 20 10. Mar 20 -13,857 €4.49 €-60,908
28. Feb 20 Sell David Gionco Individual 25. Feb 20 25. Feb 20 -9,147 €5.91 €-54,063
28. Feb 20 Sell Ivan Bergstein Individual 25. Feb 20 25. Feb 20 -24,642 €5.90 €-145,419
28. Feb 20 Sell Kenneth Hoberman Individual 25. Feb 20 25. Feb 20 -11,547 €5.90 €-68,142
14. Feb 20 Sell Robert Francomano Individual 07. Feb 20 07. Feb 20 -5,064 €6.14 €-31,083
24. Jan 20 Sell Kenneth Hoberman Individual 22. Jan 20 22. Jan 20 -22,139 €6.33 €-140,169
10. Jan 20 Sell Kenneth Hoberman Individual 08. Jan 20 08. Jan 20 -13,228 €9.33 €-123,443
03. Jan 20 Sell Kenneth Hoberman Individual 23. Dec 19 27. Dec 19 -46,312 €9.82 €-449,203
03. Jan 20 Sell David Gionco Individual 23. Dec 19 27. Dec 19 -4,517 €9.82 €-43,813
03. Jan 20 Sell Ivan Bergstein Individual 23. Dec 19 27. Dec 19 -56,028 €9.82 €-543,443
03. Jan 20 Sell Robert Francomano Individual 23. Dec 19 27. Dec 19 -2,670 €9.82 €-25,898
06. Dec 19 Buy Alan Forman Individual 04. Dec 19 04. Dec 19 1,000 €8.77 €8,775
04. Dec 19 Buy Alan Forman Individual 02. Dec 19 02. Dec 19 1,000 €9.28 €9,281
17. Aug 19 Sell Ivan Bergstein Individual 14. Aug 19 14. Aug 19 -35,010 €13.22 €-462,787
28. Jun 19 Sell Kenneth Hoberman Individual 24. Jun 19 26. Jun 19 -47,115 €13.61 €-623,961
28. Jun 19 Sell Ivan Bergstein Individual 24. Jun 19 26. Jun 19 -56,316 €13.61 €-746,002
18. May 19 Sell Kenneth Hoberman Individual 14. May 19 14. May 19 -25,817 €12.73 €-328,694
X
Management checks
We assess Stemline Therapeutics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Stemline Therapeutics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

S46 News

Simply Wall St News

S46 Company Info

Description

Stemline Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of oncology therapeutics in the United States and internationally. The company offers ELZONRIS, a targeted therapy directed to the interleukin-3 receptor (CD123) for patients with blastic plasmacytoid dendritic cell neoplasm in adults, and in pediatric patients two years and older. It also developing CD123 that is in Phase I/II clinical trials for the treatment of chronic myelomonocytic leukemia and myelofibrosis, as well as acute myeloid leukemia and multiple myeloma in combination with other therapies. In addition, the company is developing SL-801, a novel oral small molecule reversible inhibitor of nuclear transport protein, which is in Phase I clinical trial for the treatment of solid and hematologic cancers; and SL-701, an immunotherapy that has completed Phase II clinical trials to treat brain cancer. Its preclinical pipeline products include SL-501, a CD123 targeted therapy; SL- 1001, an oral, selective small molecule RET kinase inhibitor targeting multiple oncology indications; and SL-901, a small molecule kinase inhibitor. Stemline Therapeutics, Inc. was founded in 2003 and is based in New York, New York.

Details
Name: Stemline Therapeutics, Inc.
S46
Exchange: DB
Founded: 2003
$206,056,520
47,372,495
Website: http://www.stemline.com
Address: Stemline Therapeutics, Inc.
750 Lexington Avenue,
Eleventh Floor,
New York,
New York, 10022,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqCM STML Common Stock Nasdaq Capital Market US USD 30. Jan 2013
DB S46 Common Stock Deutsche Boerse AG DE EUR 30. Jan 2013
Number of employees
Current staff
Staff numbers
100
Stemline Therapeutics employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/08 22:17
End of day share price update: 2020/04/08 00:00
Last estimates confirmation: 2020/03/27
Last earnings filing: 2020/03/16
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.